

Table SII. Previous treatment before intravenous immunoglobulins (IVIG), reason for IVIG and concomitant drugs under IVIG

Patient	Initial dose IS	Reason for initiation of IVIG			No response, duration, months	Concomitant drug(s) at initiation of IVIG
		Relapse (dose at time of relapse)	Time to relapse, months	Side-effects of IS		
1	P 150 mg MMF 3 g	<b>P 5 mg</b> <b>MMF 1g</b>	34			P 40 mg MMF 3 g
2	P 150 mg AZT 150 mg *CP 50 mg *D (n.a.) *MT 30 mg/week			Osteopaenia with pathological fracture L2, toxic cardio-myopathy to CP	<b>168</b>	P 40 mg MMF 3 g D 50 mg
3	P 100 mg AZT 50 mg *MMF 3 g			Toxic hepatopathy, path. fracture lower leg	<b>94</b>	P 40 mg MMF 3 g
4	P 150 mg MMF 3 g	<b>P 80 mg</b> <b>MMF 3 g</b>	1	Glaucoma, osteoporosis		P 100 mg MMF 3 g
5	P n.a. MMF 3 g *D 150 mg			Toxic hepatopathy	<b>36</b>	P 100 mg MMF 3 g D 150 mg
6	P 200 mg *MMF 3 g	<b>P 5 mg</b> <b>MMF 2 g</b>	31	Deep vein thrombosis, osteopaenia		P 60mg MMF 3g
7	P 150 mg MMF 3 g *D 100 mg				<b>6</b>	P 40 mg MMF 3 g D 100 mg
8	P 130 mg MMF 3 g *D 50 mg *AZT 150 mg	<b>P 60 mg</b> <b>MMF 3 g</b>	2	TEN, osteoporosis, steroid-induced diabetes		P 20 mg AZT 150 mg
9	P 150 mg MMF 3 g			Diarrhoea, nausea, massive weight loss	<b>5</b>	P 30 mg MMF 3g
10	P 250 mg *MMF 3 g *D 100 mg	<b>P 25 mg</b>	6		3	P 80 mg MMF 3 g
11	P 250 mg MMF 3 g *D 100 mg			Steroid-induced diabetes, osteoporosis	<b>2</b>	P 50 mg
12	P 32 mg *Resochin n.a. *P 150 mg *MMF 3 g				<b>124</b>	P 80 mg MMF 3 g
13	P 150 mg MMF 3 g	<b>P 80 mg</b> <b>MMF 3 g</b>	<1	Abdominal cramps		P 40 mg MMF 3 g
14	P 150 mg AZT 100 mg *MMF 3 g *D 50 mg	<b>P n.a.</b> <b>AZT 100 mg</b>	15			P 70 mg MMF 3 g D 50 mg
15	P 150 mg AZT 100 mg *MMF 3 g *D 100 mg			Toxic hepatopathy	<b>5</b>	P 80 mg D 100 mg
16	P 80 mg *P200 mg *MMF 3 g	<b>P 7.5 mg</b>	7		3	P 40 mg MMF 3 g

Immunosuppressive agents (IS) include: prednisolone (P), azathioprine (AZT), mycophenolate mofetil (MMF), dapsone (D), cyclophosphamide (CP), and methotrexate (MT).

\*Additional IS were initiated after non-response, relapse or serious side-effects to therapy.

n.a.: detailed data not available because patient was initially treated at another centre; TEN: toxic epidermal necrolysis.

The major reason for the initiation of IVIG is shown in bold.